Posted by Michael Wonder on 07 Sep 2016
Eribulin in liposarcoma: added benefit not proven
1 September 2016 - Neither results from a study of direct comparison nor from an indirect comparison were suitable.
Eribulin mesylate (Halaven) has been approved since May 2016 for the treatment of adults with advanced liposarcoma. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added clinical benefit over the appropriate comparator therapy in these patients.
According to the findings, the dossier contained no data suitable for the assessment: in the only study of direct comparison, the dosage of the medicine in the comparator arm was not in compliance with the approval. It was not ensured in an indirect comparison that the respective patient populations were sufficiently similar. An added clinical benefit of eribulin mesylate is therefore not proven.
